Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

Healthcare is undervalued despite being a top sector for earnings growth. Read more on attractive investments among ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up to release their own treatments, aiming to challenge the two industry ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Unrestricted funds (educational activities): Abbott, Dexcom, Eli Lilly, Medtronic, Merck ... but it’s not totally unprecedented in the history of pharmaceutical blockbusters. The volume of ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said ...

Eli Lilly and Company is expanding its manufacturing footprint in Ireland with a $1.8B investment to boost production of ...

New investment will enhance global medicine production, benefiting millions of patients worldwide ...

Eli Lilly has again upped the ante in scaling up its manufacturing footprint, this time revealing an investment totaling $1.8 billion to expand production capacity at two plants in Ireland. | Eli ...

Indianapolis-based Eli Lilly and Co. on Thursday announced plans to spend $1.8 billion on two of its manufacturing sites in Ireland to boost production of medicines for Alzheimers ...

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...